임상 레이더 AI | ||
|---|---|---|
임상시험 NCT07340554 (ACT)은(는) 대마 사용, 대마 의존, 대마 사용 장애, 대마 남용, 대마초 중독, 대마 흡연, Cannabis Withdrawal, 대마초 관련 장애, Cannabis Abuse, in Remission, Cannabis Abuse, Episodic Use, 마리화나, 마리화나 남용, 마리화나 사용, 마리화나 흡연, Marijuana Dependence, Marijuana User, Marijuana-Related Disorder, Marijuana Use Disorder, 중독, 물질 중독, 물질 사용, 물질 사용 장애들, 물질 의존, 물질 남용, Substance Related Problem, Substance Abuse Drug Chronic에 대해 모집중 상태입니다. 모든 세부 정보를 보려면 임상시험 레이더 카드 뷰와 AI 발견 도구를 확인하거나 여기에서 무엇이든 물어보세요. | ||
하나의 임상시험이 필터 기준과 일치합니다.
카드 뷰
검색으로 돌아가기
인디애나 대학교Neuroimaging of Adolescent Cannabis Use Treatment (ACT) 80 자택 청소년 비대면
임상시험 세부 정보는 주로 영어로 제공됩니다. 하지만 임상 레이더 AI가 도와드릴 수 있습니다! '임상시험 설명'를 클릭하여 선택한 언어로 임상시험 정보를 확인하고, 이에 대해 AI와 논의해 보세요.
임상시험 NCT07340554 (ACT)은(는) 대마 사용, 대마 의존, 대마 사용 장애, 대마 남용, 대마초 중독, 대마 흡연, Cannabis Withdrawal, 대마초 관련 장애, Cannabis Abuse, in Remission, Cannabis Abuse, Episodic Use, 마리화나, 마리화나 남용, 마리화나 사용, 마리화나 흡연, Marijuana Dependence, Marijuana User, Marijuana-Related Disorder, Marijuana Use Disorder, 중독, 물질 중독, 물질 사용, 물질 사용 장애들, 물질 의존, 물질 남용, Substance Related Problem, Substance Abuse Drug Chronic에 대해 알아보는 중재연구입니다. 현재 상태는 모집중이며, 연구는 2026년 4월 1일에 시작되어 80명의 참여자를 모집하고 있습니다. 인디애나 대학교이(가) 진행하며, 2030년 7월 1일까지 완료될 예정입니다. ClinicalTrials.gov의 가장 최근 정보는 2026년 3월 24일에 갱신되었습니다.
간단한 개요
This study is testing whether brain activity related to learning can help predict how well teens respond to a treatment program designed to reduce cannabis use. Teens ages 14-17 will complete a brain scan and then take part in 10 weekly virtual sessions where they report cannabis use and complete drug tests at home. Participants can earn prizes for staying cannabis-free.
상세한 설명
This is a 13-week clinical trial to examine whether success during contingency management treatment for cannabis use is associated with baseline functioning of instrumental learning neuro-circuitries. The investigators propose to recruit N=80 youths ages 14-17 with varying levels of cannabis use. Following phone prescreening, participants will undergo informed consent/assent and eligibility assessment with an in-pers...더 보기
공식 제목
Neuroimaging of Instrumental Learning Networks in Adolescent Cannabis Use Treatment
질환명
대마 사용대마 의존대마 사용 장애대마 남용대마초 중독대마 흡연Cannabis Withdrawal대마초 관련 장애Cannabis Abuse, in RemissionCannabis Abuse, Episodic Use마리화나마리화나 남용마리화나 사용마리화나 흡연Marijuana DependenceMarijuana UserMarijuana-Related DisorderMarijuana Use Disorder중독물질 중독물질 사용물질 사용 장애들물질 의존물질 남용Substance Related ProblemSubstance Abuse Drug Chronic기타 연구 식별자
NCT 번호
실제 연구 시작일
2026-04
최신 업데이트 게시
2026-03-24
예상 연구 완료일
2030-07
계획된 등록 인원
80
연구종류
중재연구
단계/상
해당 없음
상태
모집중
키워드
Cannabis
Marijuana
Addiction
Marijuana
Addiction
주요 목적
치료
설계 할당
해당 없음
중재 모델
단일군설계
맹검 (마스킹)
없음 (오픈 라벨)
시험군 / 개입
| 참가자 그룹/시험군 | 개입/치료 |
|---|---|
기타Contingency Management and Elastic Net Regression All participants will receive Contingency Management treatment for Cannabis Use.
An elastic net regression model will be applied to the neuroimaging data for all participants to estimate scores on the CUDIT. | 상황 관리 Contingency management is an evidence-based behavioral intervention used to treat substance use disorders, including cannabis use disorder (CUD). Contingency management operates on the principles of instrumental learning, where positive reinforcement is used to encourage desired behaviors, such as abstinence from cannabis. First, specific target behaviors are identified for reinforcement. In CUD, this is often abstin...더 보기 Elastic Net Regression We will apply an elastic net regression model to the neuroimaging data to estimate CUDIT score based on neuroimaging data. |
주요결과변수
이차결과변수
| 결과변수 | 측정값 설명 | 시간 범위 |
|---|---|---|
Cannabis use frequency | The investigators will measure cannabis use frequency via percent of days where cannabis was used over the past 30 days via the Timeline Followback Scale (Sobell and Sobell, 1992) | Past 30 days |
Cannabis Use Disorder Identification Test (CUDIT) Score | The CUDIT (Adamson et al., 2010) is a measure of cannabis use disorder symptom level. This scale is an 8-item scale that asks about cannabis use disorder symptoms over the past year and is scored on a scale of 0 (no cannabis use in the past year) to 32 (daily cannabis use, physical and psychological dependence symptoms, severe cannabis misuse). The CUDIT will be measured once at the baseline screening visit. | Baseline |
| 결과변수 | 측정값 설명 | 시간 범위 |
|---|---|---|
Total quantity of cannabis use | The investigators will measure cannabis use quantity via the Timeline Followback Scale (Sobell and Sobell, 1992). For each day participants report cannabis use on the Timeline Followback Scale, participants will be asked to estimate the number of grams of cannabis used. | Past 30 days |
Cannabis withdrawal | Cannabis withdrawal will be measured at 12 different time points via the Cannabis Withdrawal Scale (Milin, Manion, Dare, and Walker, 2008). The Cannabis Withdrawal Scale is a 16-item scale that evaluates cannabis withdrawal symptoms, such as sleep difficulties, nervousness, anxiety, tension, and cravings for cannabis. This scale will be administered at the scanning visit, each of the 10 contingency management visits, and at the follow-up visit. | 12 weeks |
Cannabis expectancy | Cannabis expectancy will be measured at 2 time points via the Marijuana Effects Expectancy Scale-Brief (Torrealday et al., 2008). The Marijuana Effects Expectancy Scale-Brief is a six item scale that measures expected effects (relaxation, reduced anxiety, cravings) of marijuana use. This scale will be administered at the scanning visit and the follow-up visit. | 12 weeks |
Proportion of negative cannabis urine drug screen | Urine drug screens will be collected at each visit (13 total). The investigators will track the proportion of urine drug screens that are negative over all visits and that are negative over the 10 contingency management visits. | 12 weeks |
참여 도우미
적격성 기준
연령대
어린이
최소 연령
14 Years
참여 가능한 성별
전체
- 14-17 year old youth
- Guardian 18 years or older
- Youth is MRI-eligible: No metal implants, prosthetics, orthodontic devices, transdermal medication patches, piercings and/or hair or eyelash extensions that cannot easily be removed, metallic ink tattoos on the neck or face, or claustrophobia, and are not pregnant
- Youth must endorse having used cannabis at least once per week over the past month
- Youth has a history of Fetal Alcohol Spectrum Disorder, intellectual disorders, pervasive development disorder or autism spectrum disorder, psychotic disorders, history of neurological problems (epilepsy, traumatic brain injury, brain tumor, cerebrovascular disease) by parent/guardian report
- Youth or caretaker who is monolingual non-English speaker
- Youth who is currently experiencing active psychosis symptoms or suicidal/homicidal ideation or who has been hospitalized within the past 6 months for psychosis or suicidality/homicidality
- Youth who is currently undergoing contingency management treatment for cannabis use disorder
인디애나 대학교National Institute on Drug Abuse (NIDA)연구 책임자
Joseph Aloi, 책임연구자, Assistant Professor, Indiana University
연구 대표 연락처
연락처: Joseph Aloi, MD, PhD, 317-278-5433, [email protected]
연락처: Katherine LeFevre, BS, 317-278-5433, [email protected]
1 1개국에 임상시험 장소
Indiana
Indiana University School of Medicine, Indianapolis, Indiana, 46202, United States
Joseph Aloi, MD, PhD, 연락처, 317-278-5433, [email protected]
Katherine LeFevre, BS, 연락처, 317-278-5433, [email protected]
모집중